About DelMar Pharmaceuticals
DelMar Pharmaceuticals is a company based in Vancouver (Canada) founded in 2010. DelMar Pharmaceuticals has raised $7.9 million across 10 funding rounds from investors including National Research Council Canada. The company has 3 employees. DelMar Pharmaceuticals has completed 1 acquisition, including Adgero Biopharma. DelMar Pharmaceuticals operates in a competitive market with competitors including Jazz Pharmaceuticals, Insitro, BridgeBio, ATAI and C4 Therapeutics, among others.
- Headquarter Vancouver, Canada
- Employees 3
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website delmarpharma.com
- Social LinkedIn X
- Legal Name Delmar Pharmaceuticals, Inc.
- Total Equity Funding$7.9M (USD)
in 10 rounds
- Investors
- Employee Count3
- Investments & Acquisitions
Funding Insights of DelMar Pharmaceuticals
DelMar Pharmaceuticals has successfully raised a total of $7.9M across 10 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.9M
- Total Rounds 10
- First Round $5.4M
(Jan 2013)
- Investors Count 1
All 10 funding rounds of DelMar Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2020 | – | Post-IPO | – | – | – |
| Jan 2017 | $295,976 | Grant | – | – | |
| May 2016 | $5.6M | Post-IPO | – | – | – |
| Aug 2015 | $2.6M | Post-IPO | – | – | – |
| Jul 2014 | $181,617 | Grant | – | – | – |
| Mar 2013 | $10.5M | Post-IPO | – | – | – |
| Feb 2013 | $1.6M | Post-IPO | – | – | – |
| Feb 2013 | $1M | Series A | – | – | – |
| Jan 2013 | $1.5M | Series A | – | – | – |
| Jan 2013 | $5.4M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in DelMar Pharmaceuticals
DelMar Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include National Research Council Canada.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Scientific and technological research is conducted for Canada's benefit. | 1916 | nrc.canada.ca | Ottawa, Canada |
Investor details for DelMar Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of DelMar Pharmaceuticals
4 people are tracked at DelMar Pharmaceuticals (1 in leadership, 3 in board & advisors); the tracked headcount is 3.
| Name | Role | Group |
|---|---|---|
Robert E. Hoffman | President, CEO, CFO & Chairman | Leadership |
Laura Johnson | Director | Board & advisors |
Tamara A. Favorito | Director | Board & advisors |
Robert J. Toth , Jr. | Director | Board & advisors |
Complete people profiles for DelMar Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by DelMar Pharmaceuticals
DelMar Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Adgero Biopharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Photodynamic therapy for cutaneous metastatic breast cancer is developed. | adgerobiopharm.com | Princeton, United States | 2012 | Jun 2020 | •••• |
Complete acquisition details for DelMar Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of DelMar Pharmaceuticals
5 dated milestones of DelMar Pharmaceuticals across 10 years, from founding to its latest funding, stage changes and deals.
- Founded DelMar Pharmaceuticals is founded.
- Funding First funding round of $5.4M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Adgero Biopharma.
- Funding Latest funding round, Post-IPO,.
Competitors of DelMar Pharmaceuticals
DelMar Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Insitro, BridgeBio, ATAI and C4 Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. |
Detailed competitors of DelMar Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of DelMar Pharmaceuticals
The website of DelMar Pharmaceuticals (delmarpharma.com) receives about 3.6K visits a month and ranks #5,760,147 among all websites worldwide, #6,236 in Biotechnology and Pharmaceuticals.
- Monthly visits3.6K
▲ 21% vs previous month
- Unique visitors1.2K
per month
- Global rank#5,760,147
among all websites
- Category rank#6,236
Health · Biotechnology and Pharmaceuticals
- Bounce rate37%
- Pages per visit1.6
- Average visit25 sec
- DevicesDesktop 22% · Mobile 78%
Websites whose visitors overlap most with DelMar Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| astx.com | 100% | 8.9K | #2,592,392 | View details | |
| alexza.com | 100% | – | – | View details | |
us.sandoz.com | us.sandoz.com | 99% | – | – | – |
| afnm.com | 99% | – | – | View details | |
| innovuspharma.com | 81% | – | – | View details |
Latest news on Delmar Pharmaceuticals
Complete news archive for DelMar Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to DelMar Pharmaceuticals
10 companies that operate in the same segment as DelMar Pharmaceuticals (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about DelMar Pharmaceuticals
DelMar Pharmaceuticals was founded in 2010 and raised its 1st funding round 3 years after it was founded.
DelMar Pharmaceuticals is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
DelMar Pharmaceuticals is a funded company, having raised a total of $7.9M across 10 funding rounds to date. The company's 1st funding round was a Series A of $5.4M, raised on Jan 2013.
DelMar Pharmaceuticals has 3 employees.
DelMar Pharmaceuticals was founded in 2010 and is headquartered in Vancouver, Canada. Operations center on the development of small molecule chemotherapies within the biotechnology sector. The lead candidate, VAL-083, targets refractory glioblastoma multiforme, with additional exploration for front-line glioblastoma and solid tumors such as non-small cell lung cancer and ovarian cancer. Focus remains on orphan cancer indications.
DelMar Pharmaceuticals's top competitors include Jazz Pharmaceuticals, Spark Therapeutics and BridgeBio.
DelMar Pharmaceuticals has made 1 acquisition, including Adgero Biopharma.
DelMar Pharmaceuticals has 1 investor. Key investors include National Research Council Canada.
DelMar Pharmaceuticals operates through Delmar Pharmaceuticals, Inc..